Thymic Health: A Hidden Key to Immunotherapy Success?
In this article
Routine computed tomography (CT) images were used by AI to calculate a thymic health score. In a large study of 3,476 cancer patients, this showed a strong association with immunotherapy outcomes .
This association remained independent of established biomarkers such as PD-L1 and TMB .
Furthermore, in the TRACERx-NSCLC validation study, the thymic health score was also consistent with T-cell diversity and adaptive immune activity .
Immune checkpoint inhibitor (ICI) immunotherapies can produce durable responses in many cancers, but predicting who will benefit remains difficult. Biomarkers such as PD‑L1 and TMB provide a largely tumor-centered perspective. Thymic health brings the host's immune capacity into focus, suggesting a new, complementary "host-focused" biomarker paradigm.
- Clinical reality: Almost all patients already undergo chest CT; no additional imaging is needed.
- Practical potential: Automated, reproducible, and suitable for layered risk stratification in treatment selection.
- Biological rationale: Healthier thymus → more diverse T-cell pool → greater chance of ICI success.
🔍 What Is Thymic Health, and How Is It Measured?
The thymusis a central immune organ in the upper chest responsible for T-lymphocyte maturation. After puberty, it gradually shrinks and is replaced by fat, a process called thymic involution . The degree varies between individuals and may influence immune response capacity.
The researchers used routine chest CT (computed tomography) images to analyze thymic shape, volume, and density with a deep-learning (AI) algorithm, defining a "thymic health score" for each patient. A higher score indicates better-preserved thymic structure and potentially stronger immune responses.
The analyses also measured T-cell receptor (TCR) diversity . TCRs allow each T cell to recognize antigens. Greater diversity enables the immune system to respond to a broader range of threats. The positive relationship between thymic health and TCR diversity and adaptive immune signaling was regarded as strong biological validation.
📊 HR 0.65
With high versus low thymic health, progression risk was lower (PFS).
❤️ HR 0.56
With high versus low thymic health, death risk was lower (OS).
🧬 Independence
The signal persists across PD‑L1 and TMB subgroups.
Study Design and Scope
- Cohort: 3,476 patients in a pan-cancer analysis.
- Method: Routine chest CT images analyzed using deep learning to generate a thymic health score.
- Validation: In the TRACERx‑NSCLC subanalysis, association with TCR diversity and adaptive immune signaling .
- Statistics: Models adjusted for age and sex; subgroup analyses stratified by PD‑L1 and TMB.
📈 Signals by Subgroup (NSCLC Examples)
| Subgroup | Avg vs Low HR (95% CI) | High vs Low HR (95% CI) |
|---|---|---|
| PD‑L1 < 1 | 0.60 (0.42–0.86) | 0.56 (0.38–0.84) |
| PD‑L1 1–49 | 0.68 (0.52–0.89) | 0.63 (0.45–0.89) |
| PD‑L1 ≥ 50 | 0.55 (0.39–0.78) | 0.61 (0.41–0.89) |
| TMB < 10 mut/Mb | 0.64 (0.51–0.81) | 0.59 (0.46–0.77) |
| TMB ≥ 10 mut/Mb | 0.68 (0.52–0.88) | 0.63 (0.45–0.87) |
Note: All analyses adjusted for age and sex. Data compiled from ESMO 2025 abstract 108O.
Biological Validation: What Does It Show?
- In the TRACERx‑NSCLC cohort, higher thymic health, was associated with greater TCR diversity .
- Adaptive immune signaling pathways were enriched.
- This parallel links the imaging score to functional immune capacity .
💬 DROZDOGAN Academy Commentary
This study reminds us that oncology biomarkers are not limited to tumor molecular characteristics. Thymic health may indicate the "immune reserve" that determines immunotherapy efficacy. Future treatment decisions may therefore consider overall immune capacity as well as tumor tissue.
- Derived from routine CT images, this score requires no additional procedure or cost and can contribute to patient selection .
- In patients with low thymic health, combination immunotherapies or immune-supporting agents may become more rational.
- Changes in the thymic score during follow-up may reflect the immune system's dynamic capacity .
- In the near future, this approach may be evaluated as a new stratification factor in prospective clinical trials .
In short, thymic health may be an early sign of the shift in cancer treatment from tumor-centered to immune-centered medicine .
⚠️ Limitations and Cautions
- Prospective validation is needed: Current data come from a congress abstract; standardization and external validation are essential.
- Technical heterogeneity: Differences between scanners/protocols and age-related thymic involution require careful adjustment.
- Safety: The effect of high immune capacity on immune-related adverse event risk remains unclear.
Conclusion & Future Outlook
Thymic healthis a promising metric that complements tumor-centered biomarkers and brings host biology into focus. Automated calculation from routine CT supports widespread implementation . To achieve clinical adoption, prospective, multicenter studies and software/QA standards are critical.
Source Note
This content was compiled from the ESMO 2025 abstract presentation and press releases. Click below to open related links in a new tab: ESMO Press Release • ASCO Post Article
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.